nitroglycerin has been researched along with Angina, Stable in 19 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
Angina, Stable: Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hemodynamic signals were recorded at baseline and during adenosine-induced hyperemia, before and after nitroglycerin administration." | 5.19 | Wave speed in human coronary arteries is not influenced by microvascular vasodilation: implications for wave intensity analysis. ( Clapp, B; De Silva, K; Lockie, TP; Lumley, M; Perera, D; Rolandi, MC; Siebes, M; Spaan, JA, 2014) |
| "This study sought to examine the efficacy of ranolazine versus placebo on weekly angina frequency and sublingual nitroglycerin use in subjects with type 2 diabetes mellitus, coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment with up to 2 antianginal agents." | 5.17 | Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). ( Arnold, SV; Belardinelli, L; Ben-Yehuda, O; Chaitman, BR; Jones, PG; Katz, A; Kosiborod, M; Li, Y; McGuire, DK; Olmsted, A; Spertus, JA; Yue, P, 2013) |
| " As a result of the proposed method of treatment had improved the clinical course of CCH due to lower body weight, body mass index (BMI) and abdominal obesity indexes (AOI), which were characterized by decreasing the duration and frequency of angina attacks, reducing the number of nitroglycerin tablets taken, and also increased exercise tolerance (ET)." | 3.79 | [Оptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity]. ( Teslenko, IuV, 2013) |
| "This study aimed to assess the efficacy and safety of Tongxinluo capsule (TXLC) in combination with conventional therapies for treating stable angina pectoris (SAP) through a comprehensive meta-analysis and systematic review." | 3.01 | Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: A meta-analysis and systematic review. ( Feng, R; Gao, Q; Ji, X; Jiang, K; Li, Y; Lin, Q; Liu, J; Pan, Y; Qu, X; Wang, W; Wei, D; Xia, J; Xie, L; Zhang, R; Zheng, P, 2023) |
| " The primary outcomes include: the frequency of angina pectoris attack; the dosage of nitroglycerin; body limited dimension of Seattle Angina Questionnaire." | 2.79 | Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial. ( Du, Y; Kong, D; Liu, Y; Wang, Y; Yang, G; Zhang, F; Zhang, H; Zhang, Z, 2014) |
| "Chronic stable angina is a significant problem in older adults." | 2.52 | Pharmacologic management of chronic stable angina. ( Dixit, D; Kimborowicz, K, 2015) |
| "Participants aged 60 years or more with ischemic heart disease and without a history of hip fracture from The Health Improvement Network, an electronic medical records database in the United Kingdom, were included." | 1.46 | Intermittent Nitrate Use and Risk of Hip Fracture. ( Kiel, DP; Lu, N; Misra, D; Neogi, T; Peloquin, C; Zhang, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (89.47) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, X | 3 |
| Yang, S | 3 |
| Lu, J | 3 |
| Li, Y | 7 |
| Zhao, Y | 3 |
| Li, D | 3 |
| Wang, X | 4 |
| Liu, L | 3 |
| Wu, M | 3 |
| Feng, R | 1 |
| Lin, Q | 1 |
| Wei, D | 1 |
| Zhang, R | 1 |
| Jiang, K | 1 |
| Xie, L | 1 |
| Xia, J | 1 |
| Zheng, P | 1 |
| Ji, X | 1 |
| Wang, W | 1 |
| Qu, X | 1 |
| Gao, Q | 1 |
| Pan, Y | 1 |
| Liu, J | 1 |
| Qi, Y | 1 |
| Yu, C | 1 |
| Tang, L | 1 |
| Li, S | 1 |
| Sun, X | 1 |
| Gao, JW | 1 |
| Gao, XM | 1 |
| Zou, T | 1 |
| Zhao, TM | 1 |
| Wang, DH | 1 |
| Wu, ZG | 1 |
| Ren, CJ | 1 |
| Geng, NZ | 1 |
| Zhao, MJ | 1 |
| Liang, QM | 1 |
| Feng, X | 1 |
| Yang, BS | 1 |
| Shi, JL | 1 |
| Hua, Q | 1 |
| Sepehri, ZS | 1 |
| Masoomi, M | 1 |
| Ruzbehi, F | 1 |
| Kiani, Z | 1 |
| Nasiri, AA | 1 |
| Kohan, F | 1 |
| Sheikh Fathollahi, M | 1 |
| Kazemi Arababadi, M | 1 |
| Kennedy, D | 1 |
| Asadikaram, GA | 1 |
| Kosiborod, M | 2 |
| Arnold, SV | 2 |
| Spertus, JA | 2 |
| McGuire, DK | 2 |
| Yue, P | 2 |
| Ben-Yehuda, O | 2 |
| Katz, A | 1 |
| Jones, PG | 1 |
| Olmsted, A | 1 |
| Belardinelli, L | 1 |
| Chaitman, BR | 1 |
| Hambrecht, R | 1 |
| Berra, K | 1 |
| Calfas, KJ | 1 |
| Teslenko, IuV | 1 |
| Rolandi, MC | 1 |
| De Silva, K | 1 |
| Lumley, M | 1 |
| Lockie, TP | 1 |
| Clapp, B | 1 |
| Spaan, JA | 1 |
| Perera, D | 1 |
| Siebes, M | 1 |
| Akyildiz, ZI | 1 |
| Ergene, O | 1 |
| Zhang, Z | 1 |
| Zhang, F | 1 |
| Wang, Y | 1 |
| Du, Y | 1 |
| Zhang, H | 1 |
| Kong, D | 1 |
| Liu, Y | 1 |
| Yang, G | 1 |
| Dixit, D | 1 |
| Kimborowicz, K | 1 |
| Mitsutake, Y | 1 |
| Ueno, T | 1 |
| Ikeno, F | 1 |
| Yokoyama, S | 1 |
| Sasaki, K | 1 |
| Nakayoshi, T | 1 |
| Itaya, N | 1 |
| Chibana, H | 1 |
| Sasaki, M | 1 |
| Fukumoto, Y | 1 |
| Page, RL | 1 |
| Ghushchyan, V | 1 |
| Read, RA | 1 |
| Hartsfield, CL | 1 |
| Koch, BR | 1 |
| Nair, KV | 1 |
| Ancona, MB | 1 |
| Tanaka, A | 1 |
| Latib, A | 1 |
| Jabbour, RJ | 1 |
| Kawamoto, H | 1 |
| Regazzoli, D | 1 |
| Mangieri, A | 1 |
| Colombo, A | 1 |
| Misra, D | 1 |
| Peloquin, C | 1 |
| Kiel, DP | 1 |
| Neogi, T | 1 |
| Lu, N | 1 |
| Zhang, Y | 1 |
| Reeder, DN | 1 |
| Gillette, MA | 1 |
| Franck, AJ | 1 |
| Frohnapple, DJ | 1 |
| Boden, WE | 1 |
| Finn, AV | 1 |
| Patel, D | 1 |
| Peacock, WF | 1 |
| Thadani, U | 1 |
| Zimmerman, FH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus[NCT01425359] | Phase 4 | 949 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial[NCT02611596] | 0 participants (Actual) | Interventional | 2016-11-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks.~For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment." (NCT01425359)
Timeframe: 6 weeks
| Intervention | angina attacks per week (Mean) |
|---|---|
| Placebo | 5.2 |
| Ranolazine | 4.5 |
Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment. (NCT01425359)
Timeframe: 6 weeks
| Intervention | nitroglycerin uses per week (Mean) |
|---|---|
| Placebo | 3.6 |
| Ranolazine | 2.9 |
The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved). (NCT01425359)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.9 |
| Ranolazine | 4.0 |
(NCT01425359)
Timeframe: 6 weeks
| Intervention | percentage of weeks (Mean) |
|---|---|
| Placebo | 50 |
| Ranolazine | 54 |
For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined. (NCT01425359)
Timeframe: 6 weeks
| Intervention | percentage of weeks (Mean) |
|---|---|
| Placebo | 41 |
| Ranolazine | 46 |
The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey. (NCT01425359)
Timeframe: Up to 8 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mental Component Score | Physical Component Score | |
| Placebo | 1.2 | 1.9 |
| Qualifying Phase: Participants Entered a 2-week Washout Period | 1.0 | 2.8 |
3 reviews available for nitroglycerin and Angina, Stable
| Article | Year |
|---|---|
Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: A meta-analysis and systematic review.
Topics: Angina, Stable; C-Reactive Protein; Cholesterol; Drugs, Chinese Herbal; Humans; Lipoproteins, LDL; N | 2023 |
Pharmacologic management of chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Benzazepines; Calcium Channel Blockers; Cardiovascular | 2015 |
Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics.
Topics: Angina, Stable; Contraindications; Exercise Tolerance; Humans; Nitroglycerin; Treatment Outcome; Vas | 2012 |
7 trials available for nitroglycerin and Angina, Stable
9 other studies available for nitroglycerin and Angina, Stable
| Article | Year |
|---|---|
Comparison of serum levels of IL-6, IL-8, TGF-β and TNF-α in coronary artery diseases, stable angina and participants with normal coronary artery.
Topics: Angina, Stable; Case-Control Studies; Coronary Artery Disease; Coronary Vessels; Cross-Sectional Stu | 2018 |
Cardiology patient page. Managing your angina symptoms with nitroglycerin: what about exercise?
Topics: Angina, Stable; Angina, Unstable; Exercise; Exercise Tolerance; Humans; Nitroglycerin; Vasodilator A | 2013 |
[Оptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
Topics: Adult; Aged; Angina, Stable; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Body Weight; | 2013 |
Frequency of angina and quality of life in outpatients with stable coronary artery disease in Turkey: insights from the PULSE study.
Topics: Aged; Angina, Stable; Benzazepines; Cardiovascular Agents; Female; Heart Rate; Humans; Ivabradine; M | 2014 |
Serial changes of coronary endothelial function and arterial healing after paclitaxel-eluting stent implantation.
Topics: Acetylcholine; Aged; Angina, Stable; Angioscopy; Coronary Angiography; Coronary Artery Disease; Coro | 2016 |
Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; | 2015 |
Restored Physiological Vasomotion Imitating Intrascaffold Restenosis 3 Years After Bioresorbable Scaffold Implantation.
Topics: Absorbable Implants; Aged; Angina, Stable; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implanta | 2016 |
Intermittent Nitrate Use and Risk of Hip Fracture.
Topics: Aged; Angina, Stable; Female; Hip Fractures; Humans; Isosorbide Dinitrate; Kaplan-Meier Estimate; Ma | 2017 |
Clinical experience with ranolazine in a veteran population with chronic stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Stable; Calcium Channel | 2012 |